الصفحة 1
الصفحة 1
Thyroid Cancer : A Comprehensive Guide to Clinical Management
Paramount to this new edition is a thorough treatment of the nuclear medical aspects of diagnosing and managing the thyroid cancer patient. This includes extensive discussion of isotopes, isotope uptake and scanning procedures, radioiodine ablation and dosimetry (with or without recombinant human TSH), stunning, octreotide and FDG-PET scanning, and various alternative imaging modalities. Additional highlights include management of the scan-negative and thyroglobulin-positive patient, ultrasound of the lymph nodes, local adjuncts to therapy of metastases, low iodine diets and cookbooks, future directions in therapy, and alternative therapies when traditional surgery and radioactive iodine fail.
Thyroid Cancer : A Case-Based Approach
Now in its utilizing brand new clinical case material, this popular, user-friendly text presents the diagnosis and treatment of thyroid cancer and related clinical issues, providing clinicians in endocrinology and oncology with the best real-world strategies to properly manage the various manifestations of thyroid cancer that they may encounter. Each chapter is a case report that opens with a unique clinical presentation, followed by a description of the diagnosis, assessment and therapy, as well as the case outcome, literature review, clinical pearls and pitfalls, and bibliography. All recommendations are based on evidence-based clinical practice guidelines and recent literature. these cases illustrate treatment for both low- and high-risk differentiated thyroid cancer, including surgical approaches, radioiodine therapy, and novel chemotherapies and targeted therapies, as well as postoperative follow-up and special issues.
Thyroid Cancer
One of the main reasons for publishing this second edition of “T- roid Cancer” is the fact that the first edition has sold out. Furth- more, during the 4 years following the publication of the first edition in 2001, some progress, mainly in the basic sciences (molecular biology), has been made. The most prominent change in the clinical sciences has been the new classification of thyroid cancer, especially with relation to T1–T3 tumors. Now, tumors with a diameter of up to 2 cm are still classified T1. This new UICC classification (6th edition) follows the classification of the American Society of Pathology. These changes require a modification of the old guidelines. According to the Hedinger classification (1988) tumors with a diameter below 1 cm were classified as “papillary microcarcinoma of the thyroid”.
Practical Management of Thyroid Cancer : A Multidisciplinary Approach
Practical Management of Thyroid Cancer follows the American and European model of treating thyroid cancer according to the high standards recommended by the available guidelines. All rare and curable cancers including thyroid cancers with a good prognosis should be treated by a multidisciplinary team of experts following published guidelines. This essential volume is therefore directed not only to the management of thyroid cancer in developed countries but is also the model that will be highly attractive to the developing countries.
New Vision of Metformin in treating cancer
The anti-diabetic drug metformin is rapidly emerging as a potential anticancer agent. Metformin is a biguanide that is effective in treating type 2 diabetes and the insulin resistance syndromes, improves insulin resistance by reducing hepatic gluconeogensis and by enhancing glucose uptake by skeletal muscle. Metformin can reduce the incidence of cancers and can reduce the mortality from cancers, increase the response to treatment cancer cells when using radiotherapy and chemotherapy, reduce the likelihood of relapse. Diabetes can be a factor in the occurrence of various types of cancer, and develop a variety of cancers such as colo-rectal, pancreas and liver cancers, compared to non-diabetic patients. Incidence of various cancers is high among patients of T2DM due to insulin resistance and mitogenic effects caused by hyperglycemia.
Molecular Basis of Thyroid Cancer
Molecular Basis of thyroid Cancer brings together top-flight experts from across the globe to consider present state of the art treatment and techniques and what the future holds. The product of this effort is invaluable to endocrinologists, particularly those with an interest in the thyroid, molecular oncologists, nuclear medicine physicians and those in biotechnology intent on devising innovative therapies for cancer. "Significant advances in our understanding of thyroid cancer have occurred over the previous decade. This text discusses the molecular alterations and pathologic manifestations seen in this disease. Distinguished investigators address both the basic biology and clinical issues pertinent to our understanding and management of patients with thyroid cancer."
Essentials of Thyroid Cancer Management
Much has changed in the diagnosis and treatment of thyroid cancer over the past five years. Essentials of Thyroid Cancer Management provides clinicians from all disciplines with the information they need to manage patients correctly. Each chapter focuses on a specific clinical situation with the major points explained using tables and figures. A teaching atlas is included for neck ultrasonography and the interpretation of whole body radioiodine scans.
Management of Thyroid Cancer and Related Nodular Disease
Management of Thyroid Cancer and Related Nodular Disease is an authoritative, readable book covering all aspects of thyroid cancer. The text is extensively referenced and includes personal experience of 35 years working with patients with thyroid disorders, including thyroid nodules and thyroid cancer. The chapters are supplemented with many illustrations including pathology, thyroid and whole-body scans, ultrasounds and other nuclear medicine and radiological studies. Important questions that patients may ask their physicians are highlighted, indicating the topics the physician should cover.
Best diagnostic tools and supportive medication for cancer patients
Cancer is still a lethal disease despite the development of new effective therapies; therefore the purpose of our study was to improve the patient's outcome by looking for the best diagnostic tools, secondly to improve radiotherapy resistance since about 50% of all cancer patients are treated with it. The fir st par t of our study will be per formed in Alkhatib center and the selection of that hospital was upon its highly sensitive diagnostic tools, in which PET/ CT scan was playing a major role to improve survival as shown in few repor ts in our study, and it’s the only safe diagnostic tool for a per son who has a metal fragments after injury in the war which increased the number of such patients in our country dur ing the last decade. This diagnostic tool is based on FDGin which we can define the tumor by using sugar more than normal tissue.
